BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Idiopathic pulmonary fibrosis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for idiopathic pulmonary fibrosis: 54 (41 sponsors; 17 newly posted in the last 180 days, 3 stopped in the last 180 days; 11 new-entrant sponsors). Momentum score 23.1, rank 17 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 5, Phase 2 31, Phase 3 13, Phase 4 0, N/A 3.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Bristol-Myers Squibb BMY3P3 2, NA 110
Trevi Therapeutics TRVI new entrant2P3 220
Boehringer Ingelheim3P2 2, P3 112
Haisco Pharmaceutical Group Co., Ltd.3P2 2, P3 110
InSilico Medicine Hong Kong Limited2P2 1, P3 110
PureTech PTCHF2P3 1, P2 100
Sunshine Lake Pharma Co., Ltd. SBFM2P2 1, P3 100
Beijing Tide Pharmaceutical Co., Ltd1P3 100
Guangzhou JOYO Pharma Co., Ltd1P3 101
Shanghai Ark Biopharmaceutical Co., Ltd. new entrant1P3 110
United Therapeutics UTHR1P3 100
Avalyn Pharma Inc. AVLN2P2 201
Chiesi Farmaceutici S.p.A.2P1 1, P2 110
Shanghai Synvida Biotechnology Co.,Ltd.2P2 1, EARLY_P1 102
AbbVie ABBV1P2 100
Agomab Spain S.L.U. new entrant1P2 110
AstraZeneca AZN new entrant1P2 110
Calluna Pharma AS1P2 100
Contineum Therapeutics CTNM1P2 100
Cosmos Rx, Inc COSG new entrant1NA 110
Cough Monitoring Medical Solutions1NA 100
CSPC-NBP Pharmaceutical Co., Ltd. new entrant1P2 110
Cumberland Pharmaceuticals CPIX1P2 100
Daewoong Pharmaceutical Co. LTD.1P2 100
Dragonboat Biopharmaceutical Company Limited1P2 100

New-entrant sponsors: Trevi Therapeutics, Shanghai Ark Biopharmaceutical Co., Ltd., Agomab Spain S.L.U., AstraZeneca, Cosmos Rx, Inc, CSPC-NBP Pharmaceutical Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Sunshine Lake Pharma Co., Ltd. SBFMNCT05139719 A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung DisProgressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)recruiting110
2026-12 est.P2Avalyn Pharma Inc. AVLNNCT07194382 AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFIdiopathic Pulmonary Fibrosis (IPF)recruiting160
2026-12 est.P2Pulmovant, Inc.NCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILDPulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases; Vascular Diseases; Cardiovasrecruiting20
2026-12-31 est.P2/P3Guangzhou JOYO Pharma Co., LtdNCT06125327 SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosisrecruiting210
2026-12-31 est.P2Shanghai Synvida Biotechnology Co.,Ltd.NCT07121413 A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis(IPF)recruiting48

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2Calluna Pharma ASNCT06736990 A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosisactive not recruiting150
2026-10-31 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07019090 Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)not yet recruiting120
2026-10-13 est.P2Daewoong Pharmaceutical Co. LTD.NCT05389215 Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPFIdiopathic Pulmonary Fibrosisactive not recruiting102
2026-10-06 est.P3Bristol-Myers Squibb BMYNCT06003426 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosisactive not recruiting1255
2026-08-27P2Syndax Pharmaceuticals SNDXNCT06132256 MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosiscompleted145
2026-08-21P2Endeavor Biomedicines, Inc.NCT06422884 A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)Idiopathic Pulmonary Fibrosis; Progressive Fibrosing Interstitial Lung Diseasecompleted213
2026-08-05P2Boehringer IngelheimNCT06241560 A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodIdiopathic Pulmonary Fibrosiscompleted20
2026-07-21P2SPARK Biopharma SPKLFNCT06747923 SB17170 Phase 2 Trial in IPF PatientsIPF; Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)completed32
2026-05-26P2Pulmovant, Inc.NCT06635850 A Study of Mosliciguat in PH-ILDPulmonary Hypertension; Interstitial Lung Disease; Lung Diseases; Vascular Diseases; Cardiovascular active not recruiting135

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "idiopathic pulmonary fibrosis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.